# US 2020/0390940 A1 · Composition comprising hyaluronic acid and mepivacaine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390940 A1
- Document ID: US20200390940A1
- Status: Published application
- Kind: A1
- Application number: 17/003,377
- Filed: 2020-08-26
- Published: 2020-12-17
- Earliest claimed: 2013-07-30
- Assignees: Teoxane
- Applicants: Teoxane
- Inventors: Francois Bourdon; Stephane Meunier
- Web page: https://patentgrep.com/patent/US20200390940A1

## CPC

- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61K 8/24: Phosphorous; Compounds thereof
- A61K 8/4926: {having six membered rings}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/728: Hyaluronic acid
- A61K 47/02: Inorganic compounds
- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 27/20: Polysaccharides
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 19/00: Drugs for skeletal disorders
- A61P 23/00: Anaesthetics
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/524: Preservatives
- A61K 2800/75: Anti-irritant
- A61K 2800/91: Injection
- A61L 2300/204: with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2400/06: Flowable or injectable implant compositions
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

## Claims

### Claim 1

A composition that is sterilized and injectable,
the composition comprising an effective amount of:
at least hyaluronic acid or a salt thereof; and
an effective amount of at least mepivacaine or a salt thereof as anesthetic agent.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the hyaluronic acid has an average molecular weight ranging from 50,000 to 10,000,000 Daltons.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the hyaluronic acid is selected from the group consisting of crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, and a mixture thereof.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the composition comprises from 0.1 to 5% by weight of hyaluronic acid relative to the total weight of the composition.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the hyaluronic acid is cross-linked with a degree of modification ranging from 0.1 to 20%.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the composition comprises from 0.01 to 5% by weight of anesthetic agent(s), based on the total weight of the composition.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the composition further comprises at least a balanced salt solution.

### Claim 8 (depends on 7)

The composition according to claim 7, wherein the balanced salt solution is a KH2PO4/K2HPO4 saline buffer.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the composition further comprises at least one compound selected from the group consisting of an alpha-lipoic acid; N-acetyl-L-cysteine; reduced glutathione; amino acid such as L-Arginine, L-Isoleucine, L-leucine, monohydrated L-Lysine, Glycine, L-Valine, L-Threonine, L-Proline; pyridoxine hydrochloride; dehydrated zinc acetate; pentahydrates copper sulfate; and a mixture thereof.

### Claim 10 (depends on 1)

An injection device comprising a composition according to claim 1.

### Claim 11 (depends on 10)

The injection device according to claim 10, wherein the hyaluronic acid has an average molecular weight ranging from 50 000 to 10 000 000 Daltons.

### Claim 12 (depends on 10)

The injection device according to claim 10, wherein the hyaluronic acid is selected from the group consisting of crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, and a mixture thereof.

### Claim 13 (depends on 10)

The injection device according to claim 10, wherein the composition comprises from

### Claim at position 14

1 to 5% by weight of hyaluronic acid relative to the total weight of the composition.

### Claim 14 (depends on 10)

The injection device according to claim 10, wherein the hyaluronic acid is cross-linked with a degree of modification ranging from 0.1 to 20%.

### Claim 15 (depends on 10)

The injection device according to claim 10, wherein the composition comprises from 0.01 to 5% by weight of anesthetic agent(s), based on the total weight of the composition.

### Claim 16 (depends on 10)

The injection device according to claim 10, wherein the composition further comprises at least a balanced salt solution, preferably the balanced salt solution is a KH2PO4/K2HPO4 saline buffer.

### Claim 17 (depends on 10)

The injection device according to claim 10, wherein said injection device is suitable for intraepidermal and/or intradermal and/or subcutaneous injection.

### Claim 18 (depends on 10)

The injection device according to claim 10, wherein said injection device is selected from a syringe, a set of microsyringes, a laser device, a hydraulic device, an injection gun, a needless injection device, a rolling with microneedles.

### Claim 19 (depends on 10)

The injection device according to claim 10, wherein said injection device adapted to the technique of mesotherapy.

### Claim 20 (depends on 10)

The injection device according to claim 10, wherein said injection device comprises a hypodermic needle or cannula.

### Claim 21 (depends on 20)

The injection device according to claim 20, wherein the needle or the cannula has a diameter ranging between 18 and 34 G and a length varying from 4 to 70 mm.
